ODAC Chairman Rebukes Pfizer, Data Monitoring Committee Over Sutent Trial Conduct
Executive Summary
The actions by Pfizer and its independent Data Monitoring Committee in terminating a Sutent clinical trial may have benefitted the study’s placebo subjects, but were a disservice to the larger community of patients with pancreatic neuroendocrine tumors, the chairman of FDA’s Oncologic Drugs Advisory Committee said April 12.
You may also be interested in...
Sutent Pancreatic Tumor Study Shows Regulatory Pitfalls Of Stopping Early
Pfizer’s development of Sutent (sunitinib) for treatment of pancreatic tumors shows the potential pitfalls sponsors face when they decide to terminate clinical trials early due to positive results.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.